NAS:EDIT (USA)   Healthcare » Biotechnology
Editas Medicine Inc logo

Editas Medicine Inc $ 32.80 1.51 (4.83%)

Volume:
1,770,411
Avg Vol (1m):
1,532,777
Market Cap $:
2.22 Bil
Enterprise Value $:
1.63 Bil
PE Ratio:
0.00
PB Ratio:
3.48
Warning! GuruFocus has detected 2 Severe warning signs with EDIT. Click here to check it out.
Also Trade In: Germany UK
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

EDIT News and Headlines - Editas Medicine Inc

GuruFocus Articles Total 16
  • 1

The stock of Editas Medicine (NAS:EDIT, 30-year Financials) is estimated to be possible value trap, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value

0 Views    GF Value    2021-05-08 22:12
Investment company DDD Partners, LLC (Current Portfolio) buys Target Corp, Schwab US Dividend Equity ETF, Magna International Inc, VMware Inc, SPDR Gold Shares ETF, sells Rayonier Advanced Materials Inc, Eaton Corp PLC, Spotify Technology SA, Schwab U.S. Small-Cap ETF, Schwab Fundamental U.S. Small Company Index ETF during the 3-months ended 2021Q1, according to the most recent filings of the investment company, DDD Partners, LLC. As of 2021Q1, DDD Partners, LLC owns 63 stocks with a total value of $586 million. These are the details of the buys and sells.
0 Views    insider    2021-05-03 13:38

The stock of Editas Medicine (NAS:EDIT, 30-year Financials) shows every sign of being possible value trap, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF

0 Views    GF Value    2021-03-30 23:12
Details the CEO buys this past week for the following companies: Editas Medicine, Dominion Energy, Evergy, Primo Water and Agree Realty

According to GuruFocus Insider Data, these were the largest CEO buys during the past week.

Editas Medicine

Editas Medicine Inc. (EDIT) CEO James C. Mullen bought 25,000 shares on March 2 at a price of $46.27. The price of the stock has decreased by 10.03% since then.

a58e2a5752d40ec76e77c4e9e5ba0e38.png

Editas Medicine is a U.S.-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology).

The

112 Views    Joy Hu    2021-03-08 14:49
Selling liquid holdings to support illiquid ones is a recipe for trouble

ARK Investment Management – or ARK Invest, as it usually styles itself – had a great 2020. ARK Innovation ETF (ARKK), the firm's flagship fund, returned more than 150% last year. Unsurprisingly, that white-hot performance led to a deluge of capital inflows. However, the scale of inflows, which surpassed $10 billion, was surprising.

Alas, it appears the party may be coming to an end for ARK and its high-flying ETFs. As I discussed in a previouis article, ARK's increased size, which has made it a major shareholder in a number of small cap stocks, has

719 Views    John Engle    2021-02-26 16:06
Shares up more than 500% and 300% since going public

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors might want to track the progress of those still-private firms in the event they take the initial public offering route down the line.

BioSpace's top five for 2021 are Sana Biotech (which I wrote about on Jan. 18 and which plans to make a public offering) and private companies EQRX, Nuvation Bio, ArsenalBio and Triumvira Immunologics.

Still private from the 2020 ranking are Anthos Therapeutics,

248 Views    Barry Cohen    2021-01-19 23:14
ARK Investment Management chief likes industry because of disease-curing potential

A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (TSLA).

Catherine Wood, the founder of ARK Investment Management and an early investor in the electric car company, said that investing in genomics and gene-editing stocks should be an even better longer-term play than Tesla because the technology has the potential to cure diseases. Three of her favorites in the field are Editas Medicine Inc. (EDIT), CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA), which together own the majority of gene-editing technology intellectual property.

Wood has been right on

936 Views    Barry Cohen    2021-01-08 22:36
Stock of biotech trading at more than 35% above analysts' median target

If analysts are even close to being on target, it may be time for early investors to cash in on their shares of Beam Therapeutics Inc. (BEAM). The stock of the Cambridge, Massachusetts-based biotechnology company closed at $67.68 Monday, up over 12% for the day and more than tripling since early February.

While the five analysts following the company still have it as a buy or strong buy, they assign the stock an average target price of $43. That's 35% below Monday's close, but keep in mind the experts have missed badly on the stock so far. In mid-May, I

151 Views    Barry Cohen    2020-12-07 21:47
Company shares up substantially since early February IPO

Shares of a Cambridge, Massachusetts-based biotechnology company that is taking a different approach to gene editing have gained more than 25% since its early February initial public offering.

Beam Therapeutics Inc.'s (BEAM) stock traded near $32 just days after it went public at an offering price of $17, but has since receded to $21.49. At its current price, many think the company is a bargain.

Among the optimists are the analysts at several firms that underwrote the offering, reported 24/7 Wall Street. Of course, it’s little surprise that they have a buy or outperform rating for the stock.

Jefferies started

216 Views    Barry Cohen    2020-05-18 21:21
New model can increase accuracy 50-fold

Gene-editing stocks may soon take a leap forward with the discovery of what is being billed as a one-size-fits-all DNA lock.

The three pure-play CRISPR stocks have been on the decline since early 2018. Shares of Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and leader CRISPR Therapeutics (CRSP) have magnified the declines of the broader stock indexes late last year. This is typical for a brand new speculative industry that is still trying to find its footing and is a long way from any sort of stable revenue. Still, two out of the three, CRISPR and Editas, remain significantly higher than

126 Views    Matt Winkler    2019-04-17 16:10
CRISPR stocks have been plagued with clinical holds by the FDA. But what if the treatments these speculative companies are working on can be applied in utero? New research shows they can

Genetic disorders are quite a daunting disease group to treat, but there is one major overlooked advantage in developing treatments for this disease group over others. Genetic diseases can be screened for in utero. So what? Thanks to new research published in the journal Nature Medicine, we know that they can be treated in utero as well.

This could have profound implications for the CRISPR gene-editing investment space, because it could change the regulatory landscape for the whole CRISPR approach to treatment. For better or for worse, fetuses do not have the same rights as those already born, and

244 Views    Matt Winkler    2018-10-14 17:34
Feng Zhang, cofounder of Editas Medicine, has discovered a new CRISPR Enzyme that can edit RNA, with potential applications for cystic fibrosis, Parkinson's and muscular dystrophy

Feng Zhang, one of the cofounders of Editas Medicine (EDIT), is at it again with yet another CRISPR discovery. This time it’s a new CRISPR system called CRISPR-cas13d, for a new private company he’s involved in called Arbor Biotechnologies.

Before we break this one down, those interested in CRISPR stocks should know that while developments are happening fast, none are anywhere near marketable drugs, and it could be years before anything even enters the clinic. CRISPR companies are going to have to thrive on investor optimism and new influxes of equity investments for the next several years at least. Valuations

185 Views    Matt Winkler    2018-03-16 14:14
Stanford Scientists succeeded in editing out an amyotrophic lateral sclerosis gene in human cell cultures. Here's why CRISPR-cas9 gene editing could change the process of drug discovery

Could the CRISPR-cas9 gene-editing system be the key to a cure for amyotrophic lateral sclerosis (ALS)? A new paper written by a group of Stanford graduate students and just published in the journal Nature Genetics suggests a very hopeful maybe. Here’s the background.

Back in 2011, a paper was published delineating the cause of ALS, at least in a group of families with a proven autosomal dominant genetic feature. The cause in these cases is a repeating series of six nucleotides in a gene called C9orf72. It’s sort of like a broken record in the gene, or a

334 Views    Matt Winkler    2018-03-12 14:32
Four Polish scientists just discovered a way to edit genes with CRISPR with high precision. Past CRISPR tech has hit public markets very quickly, and this new innovation may do so soon as well.

The CRISPR-cas9 gene editing technique is one of the most exciting advances in genomics since Watson and Crick discovered the chemical structure of DNA in 1953. Basically, it allows the selective editing of genes, potentially allowing humans to fix errors that cause genetic diseases and any other number of science fiction-like applications.

The main problem is CRISPR can cause mistakes in DNA after the cut strands are excised and the rest glued back together. This can lead to transcription problems, causing unforeseeable issues. That makes it very scary to apply for practical purposes because new errors can cause worse problems

308 Views    Matt Winkler    2018-03-02 20:29
Viking Global investor has a enlarged allocation to health care

Andreas Halvorsen (Trades, Portfolio) this week bought more of a stock in health care, a sector where he has increasingly invested.

Halvorsen, a Norwegian investor who founded the $30 billion hedge fund Viking Global, made health care stocks more than a third of his portfolio for the latter three quarters of 2015. His holdings spread throughout the sector, in areas such as biotech, drug manufacturing, health care plans, health care providers, medical diagnostics and research, and medical instruments and equipment.

Kite Pharma (KITE), the holding Halvorsen increased Feb. 18, is a biopharmaceutical company developing treatments for cancer.

1285 Views    Holly LaFon    2016-03-01 21:55
Viking Global buys more of Editas Medicine, a developer of technology to treat genetic diseases through fixing faulty genes

Andreas Halvorsen (Trades, Portfolio), founder of $30 billion hedge fund Viking Global Investors, on Tuesday disclosed a sizable position in the initial public offering of a company pioneering the field of gene editing technology, Editas Medicine Inc. (EDIT), which also held the first IPO of the year.

Havorsen’s Global Opportunities Illiquid Investment Sub-Master was one of the company’s seven largest equity holders before the offering, according to IPO documents. He joined a group of venture capital firms, as well as Alphabet’s Google Ventures and Bill Gates (Trades, Portfolio) in backing the company

2157 Views    Holly LaFon    2016-02-10 21:08

Headlines Total 199
  • 1
  • 2

2021-05-08
5:12pm
2021-05-05 $ 34.72 (0.17%)
2:46pm
10:05am
7:20am
6:01am
6:00am
2021-05-04 $ 34.66 (-2.61%)
8:01am
2021-05-01
7:00am
2021-04-29 $ 37.37 (-3.98%)
3:17pm
2021-04-28 $ 38.92 (-0.59%)
7:00am
2021-04-27 $ 39.15 (0.18%)
6:52am
2021-04-21 $ 35.86 (4.03%)
7:55am
2021-04-16 $ 34.67 (-15.4%)
2:39pm
2021-03-30 $ 40.5 (1.99%)
6:12pm
2021-03-27
10:31am
2021-03-25 $ 42.18 (2.9%)
8:45am
2021-03-11 $ 47.32 (1.41%)
11:06am
2021-03-09 $ 45.33 (11.82%)
11:52am
2021-03-08 $ 40.54 (-2.62%)
8:49am
2021-03-06
10:12am
2021-03-04 $ 40.36 (-6.42%)
4:15pm
4:08pm
2021-03-01 $ 46.89 (6.91%)
2:35pm
2021-02-26 $ 43.86 (-2.01%)
8:04am
2021-02-25 $ 44.76 (-9.94%)
1:40pm
2021-02-23 $ 49.14 (-6.26%)
2:29pm
2021-02-20
9:03am
2021-02-19 $ 55.36 (-2.04%)
6:59pm
2021-02-17 $ 56.51 (0.11%)
11:31am
6:30am
2021-02-16 $ 56.45 (-2.57%)
2:00pm
1:20pm
2021-02-14
5:23pm
2021-02-12 $ 57.94 (1.35%)
4:45pm
2021-02-11 $ 57.17 (-3.28%)
1:48pm
5:20am
2021-02-10 $ 59.11 (-11.42%)
5:43pm
4:42pm
2021-02-08 $ 69.75 (8.88%)
11:00am
2021-02-04 $ 63.18 (1.64%)
4:45pm
2021-01-26 $ 60.68 (-7.32%)
6:30am
2021-01-25 $ 65.47 (-0.44%)
4:45pm
3:20am
2021-01-21 $ 71.76 (-0.49%)
10:59pm
2021-01-20 $ 72.11 (-5.29%)
7:01pm
2021-01-19 $ 72.11 (-5.29%)
9:46am
2021-01-18
7:41am
2021-01-15 $ 76.14 (0.29%)
4:45pm
2021-01-12 $ 75 (-2.52%)
12:24pm
2021-01-11 $ 76.94 (-15.06%)
12:20pm
7:02am
7:00am
6:59am
6:59am
2021-01-08 $ 90.58 (1.03%)
8:01am
4:20am
2021-01-07 $ 89.66 (11.32%)
9:38am
7:42am
2021-01-05 $ 71.59 (2.11%)
7:00pm
2021-01-04 $ 71.59 (2.11%)
8:27am
2020-12-29 $ 74.87 (-11.24%)
12:27pm
2020-12-24 $ 83.53 (2.37%)
10:10am
2020-12-21 $ 83.66 (29.89%)
12:12pm
7:58am
2020-12-18 $ 62.71 (-2%)
7:01pm
6:15pm
2020-12-16 $ 63.99 (-1.45%)
7:35am
2020-12-10 $ 66.84 (32.15%)
1:03pm
11:47am
11:40am
7:01pm
2020-12-09 $ 50.58 (17.14%)
11:27am
2020-12-08 $ 43.18 (10.58%)
4:15pm
3:41pm
2020-12-07 $ 39.05 (13.22%)
11:41am
8:19am
2020-12-05
11:00am
10:32am
2020-12-01 $ 31.9 (4.28%)
4:05am
2020-11-11 $ 29.88 (-1.74%)
7:00pm
2020-11-10 $ 30.41 (-0.26%)
7:02pm
2020-11-09 $ 30.41 (-0.26%)
11:01am
2020-11-06 $ 30.49 (-3.36%)
11:20am
10:24am
10:26pm
7:03pm
2020-11-05 $ 31.55 (3.61%)
4:25pm
2020-10-30 $ 32.795 (3.77%)
7:00pm
2020-10-13 $ 32.77 (1.71%)
8:45am
2020-10-12 $ 32.22 (-2.63%)
8:45am
2020-10-09 $ 33.09 (7.75%)
11:46am
2020-10-08 $ 30.71 (-1.06%)
12:08pm
2020-10-07 $ 31.04 (7.93%)
5:05pm
2020-10-01 $ 28.17 (0.39%)
11:02am
2020-09-30 $ 28.06 (-3.37%)
6:45am
2020-09-23 $ 31.45 (-4%)
10:03am
2020-09-11 $ 29.99 (-1.35%)
5:45pm
7:00am
2020-09-09 $ 30.95 (5.81%)
4:26pm
2020-09-05
10:32am
Total 199
  • 1
  • 2